Why bluebird bio's Q4 Results Really Don't Matter
While most stocks delivered great returns in 2019, bluebird bio's (NASDAQ: BLUE) shares fell 11%. And despite a nice upswing to start off the new year, the stock is close to the level it started 2020 after giving up most of its initial gains.
Bluebird reported its fiscal 2019 fourth-quarter and full-year results after the market closed on Tuesday. Here are the highlights from the biotech's Q4 update, why its results really don't matter -- and what does matter.
Image source: Getty Images.
Source Fool.com
